| Literature DB >> 35727609 |
Sameh Gomaa1, Carly West1, Ana Maria Lopez1, Tingting Zhan2, Max Schnoll1, Maysa Abu-Khalaf1, Andrew Newberg3, Kuang-Yi Wen1.
Abstract
BACKGROUND: Estrogen receptor-positive breast cancer is the most common type of breast cancer in postmenopausal women. Aromatase inhibitors (AIs) are the endocrine therapy of choice recommended for these patients. Up to 50% of those treated with an AI develop arthralgia, often resulting in poor adherence and decreased quality of life.Entities:
Keywords: arthralgia; breast cancer; mind-body therapy; tai chi; telehealth, pain
Year: 2022 PMID: 35727609 PMCID: PMC9257610 DOI: 10.2196/34995
Source DB: PubMed Journal: JMIR Form Res ISSN: 2561-326X
Participant characteristics.
| Variable | Participants (N=39) | ||
| Age (years), mean (SD) | 58.18 (10.60) | ||
|
| |||
|
| Caucasian | 30 (77) | |
|
| African American | 7 (18) | |
|
| Asian | 1 (3) | |
|
| Unreported | 1 (3) | |
|
| |||
|
| Non-Hispanic | 38 (97) | |
|
| Hispanic | 1 (3) | |
|
| |||
|
| Married | 26 (67) | |
|
| Single | 7 (18) | |
|
| Divorced | 5 (13) | |
|
| Widowed | 1 (3) | |
|
| |||
|
| High school | 3 (8) | |
|
| College graduate | 16 (41) | |
|
| Postgraduate school | 20 (51) | |
|
| |||
|
| 0 | 2 (5) | |
|
| I | 14 (36) | |
|
| II | 17 (44) | |
|
| III | 6 (15) | |
|
| |||
|
| Mastectomy | 22 (56) | |
|
| Lumpectomy | 15 (39) | |
| Radiationa, n (%) | 27 (69) | ||
| Chemotherapya, n (%) | 23 (59) | ||
|
| |||
|
| Letrozole | 6 (15) | |
|
| Anastrozole | 21 (54) | |
|
| Exemestane | 9 (23) | |
|
| Other | 3 (8) | |
|
| |||
|
| ≤1 | 12 (31) | |
|
| 1-3 | 12 (31) | |
|
| 3-6 | 12 (31) | |
|
| Unreported | 3 (8) | |
aTreatment options do not add up to 39 due to individual treatment choices.
bAI: aromatase inhibitor.
Change in patient-reported outcomes over time.
| Measure (range) | Baseline (N=39), mean (SD) | 1 month (n=25), mean (SD) | 2 months (n=22), mean (SD) | 3 months (n=21), mean (SD) | 3-month change (95% CI)a | Linear time trend detected by the latent class model | ||
| WOMACb pain (0-20 maximal pain) | 8.05 (4.19) | 6.52 (3.70) | 6.36 (4.82) | 5.05 (3.89) | 2.57 (1.27-3.87) | <.001c | –0.51 | <.001c |
| WOMAC stiffness (0-8 maximal stiffness) | 4.36 (1.74) | 3.44 (1.61) | 3.00 (1.75) | 2.33 (1.65) | 1.67 (0.81-2.52) | <.001c | –0.77 | <.001c |
| WOMAC function (0-68 minimal function) | 23.28 (14.21) | 17.76 (12.36) | 16.32 (13.81) | 11.67 (12.70) | 8.95 (5.65-12.25) | <.001c | –0.71 | <.001c |
| BPId (0-10 worse pain) | 5.04 (2.17) | 4.22 (2.29) | 4.16 (1.82) | 2.69 (2.18) | 2.25 (1.27-3.24) | <.001 | –0.456 | <.001 |
| AUSCANe pain (0-50 worse pain) | 6.64 (4.57) | 6.00 (4.27) | 4.77 (4.08) | 3.52 (3.56) | 2.33 (0.71-3.96) | .007 | –0.642 | <.001 |
| AUSCAN function (0-90 minimal function) | 11.13 (7.63) | 8.80 (8.10) | 7.45 (7.97) | 5.71 (7.27) | 4.48 (1.62-7.33) | .004 | –0.794 | <.001 |
| FSIf (0-130 worse fatigue) | 53.40 (27.29) | 40.04 (26.53) | 36.94 (22.02) | 29.74 (20.05) | 17.53 (6.20-28.86) | .004 | –0.61 | <.001 |
| HFRDISg (0-100 worse hot flash) | 28.14 (25.46) | 19.27 (22.89) | 13.10 (14.25) | 12.44 (13.78) | 10.15 (2.04-18.26) | .02 | For 28 patients: –0.176; for 11 patients: –1.235 | For 28 patients: .14; for 11 patients: <.001 |
| PSQIh (0-21 lower sleep quality) | 18.00 (5.86) | 15.04 (6.52) | 14.55 (5.70) | 11.10 (6.40) | 6.14 (3.32-8.96) | <.001 | –0.626 | <.001 |
| CES-Di (0-60 greater depressive symptom severity) | 38.33 (5.61) | 37.40 (4.53) | 36.05 (4.46) | 33.95 (4.97) | 2.62 (0.26-4.97) | .03 | –0.353 | <.001 |
aPaired t test.
bWOMAC: Western Ontario and McMaster University Osteoarthritis Index.
cAdjusted for multiple comparison.
dBPI: Brief Pain Inventory.
eAUSCAN: Australian Canadian Osteoarthritis Hand Index.
fFSI: Fatigue Symptom Inventory.
gHFRDIS: Hot Flash Related Daily Interference Scale.
hPSQI: Pittsburgh Sleep Quality Index.
iCES-D: Center for Epidemiological Studies-Depression.